LEVIUM Wins Award for Best Non-Prescription Stress and Anxiety Relief Supplement

News provided by

Optimal Performance Living; Levium

Oct 25, 2023, 08:39 ET

LEVIUM, a natural anxiety relief supplement made by Los Angeles-based Glauser Life Sciences, Inc., has won the award for Best Non-Prescription Stress and Anxiety Relief Supplement from Optimal Performance Living, a digital publication. LEVIUM's unique formulation promises quick relief from stress and anxiety with no side effects, using natural, clinically proven ingredients that are non-addictive and safe to use with common prescription medications.

NEW YORK, Oct. 25, 2023 /PRNewswire/ -- Optimal Performance Living has announced that LEVIUM has been honored with its award for the Best Non-Prescription Stress and Anxiety Relief Supplement. A safe and effective nutraceutical, LEVIUM offers an alternative to prescription medications, using natural ingredients that balance neurotransmitters to reduce anxiety and the effects of stress. [See Full Release.]

Continue Reading
LEVIUM, a natural anxiety relief supplement made by Los Angeles-based Glauser Life Sciences, Inc., has won the award for Best Non-Prescription Stress and Anxiety Relief Supplement from Optimal Performance Living, a digital publication. LEVIUM's unique formulation promises quick relief from stress and anxiety with no side effects, using natural, clinically proven ingredients that are non-addictive and safe to use with common prescription medications.
LEVIUM, a natural anxiety relief supplement made by Los Angeles-based Glauser Life Sciences, Inc., has won the award for Best Non-Prescription Stress and Anxiety Relief Supplement from Optimal Performance Living, a digital publication. LEVIUM's unique formulation promises quick relief from stress and anxiety with no side effects, using natural, clinically proven ingredients that are non-addictive and safe to use with common prescription medications.
Industry analysts say the global anxiety treatment market is expected to reach $16.26 billion by 2029, with a compound annual growth rate (CAGR) of 5%. The market is driven by the rising incidence of anxiety illnesses and increasing government initiatives to promote mental health awareness. The global pandemic of COVID-19, stressful work environments, and sedentary lifestyles have also contributed to an increased number of anxiety disorder patients.
Industry analysts say the global anxiety treatment market is expected to reach $16.26 billion by 2029, with a compound annual growth rate (CAGR) of 5%. The market is driven by the rising incidence of anxiety illnesses and increasing government initiatives to promote mental health awareness. The global pandemic of COVID-19, stressful work environments, and sedentary lifestyles have also contributed to an increased number of anxiety disorder patients.

Anxiety disorder is a challenging mental health disease that frequently calls for medical and psychological support. Occasional feelings of anxiety are a normal part of life, but individuals who experience frequent episodes of life-interfering anxiety are said to suffer from disorders because of intense, excessive, continuous worry and even terror about commonplace events or activities. Anxiety disorders in the U.S. now affect almost 40 million people above the age of 18, presenting a significant demand for effective treatment.

Industry analysts say the global anxiety treatment market is expected to reach $16.26 billion by 2029, with a compound annual growth rate (CAGR) of 5%. The market is driven by the rising incidence of anxiety illnesses and increasing government initiatives to promote mental health awareness. The global pandemic of COVID-19, stressful work environments, and sedentary lifestyles have also contributed to an increased number of anxiety disorder patients, further driving demand for remedies such as LEVIUM.

LEVIUM's effectiveness stems from its capacity to protect and promote the neurotransmitter neuropeptide Y (NPY), a powerful anxiolytic. Known as "the resilience neurotransmitter," it counterbalances cortisol, the body's stress hormone. LEVIUM also helps increase blood flow to the brain and supports healthy neural activity. It is non-addictive and specifically designed to have no contraindications with common anti-anxiety medications and antidepressants, including SSRIs.

Glauser Life Sciences, Inc., the maker of LEVIUM, was founded in 2015 by CEO Christopher Adams. LEVIUM is currently distributed directly to consumers online, via Amazon.com, and on a wholesale basis. [See additional details.]

About

Optimal Performance Living is a digital publication serving an audience located primarily in the United States.

Media Contact:
Harold Butler
212-997-4163
[email protected] 

SOURCE Optimal Performance Living; Levium

21%

more press release views with 
Request a Demo